Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

ClinicalTrials.gov ID: NCT01034462

Public ClinicalTrials.gov record NCT01034462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder

Study identification

NCT ID
NCT01034462
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Forest Laboratories
Industry
Enrollment
442 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2009
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011
Last update posted
Oct 24, 2013

2009 – 2011

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Forest Investigative Site 055 Dothan Alabama 36305
Forest Investigative Site 065 Highlands Ranch Colorado 80130
Forest Investigative Site 057 Boca Raton Florida 33431
Forest Investigative Site 060 Boca Raton Florida 33432
Forest Investigative Site 064 Gainesville Florida 32607
Forest Investigative Site 053 Ocala Florida 34471
Forest Investigative Site 061 Orlando Florida 32806
Forest Investigative Site 059 Winter Park Florida 32789
Forest Investigative Site 070 Atlanta Georgia 30328
Forest Investigative Site 066 Smyrna Georgia 30080
Forest Investigative Site 072 Chicago Illinois 60634
Forest Investigative Site 050 Oak Brook Illinois 60523
Forest Investigative Site 063 Indianapolis Indiana 46260
Forest Investigative Site 071 Prairie Village Kansas 66206
Forest Investigative Site 052 Shreveport Louisiana 71104
Forest Investigative Site 051 Brooklyn New York 11214
Forest Investigative Site 056 Oklahoma City Oklahoma 73112
Forest Investigative Site 067 Oklahoma City Oklahoma 73112
Forest Investigative Site 058 Salem Oregon 97301
Forest Investigative Site 054 Allentown Pennsylvania 18104
Forest Investigative Site 062 San Antonio Texas 78229
Forest Investigative Site 068 Virginia Beach Virginia 23452
Forest Investigative Site 069 Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01034462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 24, 2013 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01034462 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →